Karolinska Development: EMEA Recommends Orphan Drug Designation for Acute Myeloid Leukemia Treatment

STOCKHOLM, February 18, 2010 /PRNewswire/ -- The European Medicines

Agency (EMEA) recommends orphan drug status for Aprea's treatment of acute

myeloid leukemia (AML). The treatment is currently undergoing a Phase I

clinical study and a final decision from the European Commission regarding

status

http://digg.com/u1NfNo